Yahoo Finance

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

SIOUX FALLS, S.D., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing ...
Yahoo Finance

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...
Nasdaq

SAB BIO Reports Positive Phase 1 Trial Results for SAB-142 in Type 1 Diabetes, Supporting Advancement to Phase 2b Development

SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
News24

SAB promises 'very small' number of job losses as it starts retrenchment process

South African Breweries (SAB), the local unit of global brewing giant Anheuser-Busch InBev (AB InBev), has embarked on a retrenchment process at its local operations that could affect some 40 jobs. In ...